2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations.
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020 Apr 27;: Authors: Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Lin HC, Kao JH, Chuang WL Abstract Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been reported in Taiwan, especially in high-risk populations including people who inject drugs (PWID) and patients requiring dialysis. Besides, certain populations merit special considerations due to suboptimal outcome, potential drug-drug interaction, or possible side effect. Therefore, in the second part of this 2-part consensus, the Taiwan Association for the Study of the Liver (TASL) proposes the treatment recommendations for the special population in order to serve as guidance to optimizing the outcome in the direct-acting antiviral (DAA) era. Special populations include patients with acute or recent HCV infection, previous DAA failure, chronic kidney disease, decompensated cirrhosis, HCC, liver and other solid organ transplantations, receiving an HCV viremic organ, hepatitis B virus (HBV) and HCV dual infection, HCV and human immunodeficiency virus (HIV) coinfection, active tuberculosis infection, PWID, bleeding disorders and hemoglobinopathies, children and adolescents, and pregnancy. Moreover, future perspecti...
Publication date: Available online 10 July 2020Source: Revista Clínica Española (English Edition)Author(s): J.J. Hijona Elósegui, A.L. Carballo García, A.C. Fernández Risquez, M. Bermúdez Quintana, J.F. Expósito Montes
Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Gina T. Baaklini, Misty J. Thompson, Kevin J. Krauland, Daniel R. Walker, Steven J. Hudak
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Publication date: Available online 10 July 2020Source: American Journal of Kidney DiseasesAuthor(s): Lara Meyer, Marc Ulrich, Didier Ducloux, Valérie Garrigue, Cécile Vigneau, Dominique Nochy, Guillaume Bobrie, Sophie Ferlicot, Magalie Colombat, Jean-Jacques Boffa, Karine Clabault, Jeannette Mansour, Christiane Mousson, Raymond Azar, Jean-Louis Bacri, Antoine Dürrbach, Christian Duvic, Khalil El Karoui, Maxime Hoffmann, Arnaud Lionet
Conclusions: HRU and costs from HCT to PTLD were high and more than doubled within 1-year post-PTLD. PTLD patients who died had ∼7 times higher costs than those who lived, driven by hospitalizations. Effective treatments are needed to reduce the burden of PTLD. PMID: 32643493 [PubMed - as supplied by publisher]
Authors: Śnietura M, Brewczynski A, Waniczek D, Kopec A, Stanek-Widera A, Muc-Wierzgoń M, Rutkowski T PMID: 32643355 [PubMed - in process]
Publication date: Available online 11 July 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Nikita Naredi, Pankaj Talwar, Sandeep Karunakaran
Publication date: Available online 11 July 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Tsung-Hao Liu, Yu-Yun Shao, Chih-Hung Hsu
Publication date: Available online 10 July 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Michael W. Hughes, Ping-Yen Liu
In this study, 1452 patients were enrolled. Independent risk factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed for patients with and without CSPH. For HCC patients without CSPH, multivariate analysis suggested that microvascular invasion (MVI), neutrophil-to-lymphocyte ratio (NLR) ≥ 3, platelet-to-lymphocyte ratio (PLR) ≥ 150, tumor size> 5 cm, and the presence of a satellite lesion were independently associated with RFS. MVI, NLR ≥ 3, PLR ≥ 150, and advanced Barcelona clinical liver cancer (BCLC) stage contributed to mortality. However, neither NLR nor PLR showed any prognos...
More News: Bleeding | Cancer & Oncology | Carcinoma | Children | Chronic Kidney Disease | Cirrhosis | Dialysis | General Medicine | Hepatitis | Hepatitis B | Hepatitis C | Hepatocellular Carcinoma | Kidney Transplant | Kidney Transplantation | Liver | Liver Cancer | Liver Transplant | Pregnancy | Study | Taiwan Health | Transplants | Tuberculosis | Urology & Nephrology